<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00186979</url>
  </required_header>
  <id_info>
    <org_study_id>ZD1839</org_study_id>
    <nct_id>NCT00186979</nct_id>
  </id_info>
  <brief_title>Study of ZD1839 Combined With Irinotecan and Vincristine in Pediatric Patients With Refractory Solid Tumors</brief_title>
  <official_title>A Phase I Study of ZD1839 (Iressa) in Combination With Irinotecan (Camptosar or CPT-11) and Vincristine in Pediatric Patients With Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to estimate the maximum tolerated dose of gefitinib in&#xD;
      combination with fixed dose of irinotecan and vincristine in patients with refractory solid&#xD;
      tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives of this study are:&#xD;
&#xD;
        -  To determine the dose-limiting toxicities (DLT) of the combination of irinotecan and&#xD;
           ZD1839 when given on this schedule.&#xD;
&#xD;
        -  To characterize the pharmacokinetics and pharmacodynamics of gefitinib alone and in&#xD;
           combination with irinotecan and vincristine.&#xD;
&#xD;
        -  To estimate the maximum tolerated dose (MTD) of gefitinib in combination with escalating&#xD;
           intravenous irinotecan by using selective intestinal decontamination with oral cefixime&#xD;
           or cefpodoxime to prevent diarrhea.&#xD;
&#xD;
        -  To estimate the MTD of vincristine (MTD) in combination with gefitinib and irinotecan.&#xD;
&#xD;
      Details of Treatment Interventions&#xD;
&#xD;
      First Cohort:&#xD;
&#xD;
      Standard dose escalation, starting at ZD1839 150 mg/m2/day for 21 days in combination with&#xD;
      irinotecan 15mg/m2/day on a daily x 5 for two consecutive week schedule. Dose-limiting&#xD;
      diarrhea was seen in this cohort. ZD scheduled was reduced to 12 days. The first dose level&#xD;
      (1a) consisted of ZD1839 112.5mg/m2/day for 12 days + irinotecan 15mg/m2/day daily x 5 x 2&#xD;
      and was found to be the MTD in this cohort.&#xD;
&#xD;
      Second Cohort:&#xD;
&#xD;
      Cefixime then added at 4 additional subjects were enrolled at dose level 1c, consisting of&#xD;
      ZD1839 at 112mg/m2/day + irinotecan 20mg/m2/day + cefixime 8 mg/kg/day administered once&#xD;
      daily, beginning on day -1, and continued to day 14.&#xD;
&#xD;
      Third Cohort:&#xD;
&#xD;
      Irinotecan/ZD1839/Vincristine/Cefixime- Cefixime 8 mg/kg/day administered once daily,&#xD;
      beginning on day -1, and continued to day 14, with a maximum dose of 400 mg daily + gefitinib&#xD;
      112.5 mg/m2 orally, daily for 12 days and irinotecan at 15 mg/m2 daily x 5 x 2 +1 mg/m2&#xD;
      (maximum 2mg/dose) on days 1 and 8 with escalating dose of VCR as tolerated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicities</measure>
    <time_frame>Within the first 30 days of completion of first cycle</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan, ZD1839, Vincristine, Cefixime, Cefpodoxime.</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Younger than 22 years of age.&#xD;
&#xD;
          -  Histologic verification of solid tumor malignancy at original diagnosis.&#xD;
&#xD;
          -  Has disease considered refractory to conventional therapy or no conventional therapy&#xD;
             exists.&#xD;
&#xD;
          -  Adequate performance status, bone marrow, liver and kidney function.&#xD;
&#xD;
          -  Patients must not have had any previous allergic reactions to penicillin or&#xD;
             cephalosporins&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known severe hypersensitivity to ZD1839 or any of the excipients of this product&#xD;
&#xD;
          -  Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital,&#xD;
             or St John's Wort, and CYP3A4 inhibitors&#xD;
&#xD;
          -  Treatment with a non-approved or investigational drug within 30 days before Day 1 of&#xD;
             trial treatment.&#xD;
&#xD;
          -  Incomplete healing from previous oncologic or other major surgery&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Patients who have an uncontrolled infection&#xD;
&#xD;
          -  Any evidence of clinically active interstitial lung disease (patients with chronic&#xD;
             stable radiographic changes who are asymptomatic need not be excluded).&#xD;
&#xD;
          -  As judged by the investigator, any evidence of uncontrolled systemic disease (e.g.,&#xD;
             unstable or uncompensated respiratory, cardiac, hepatic, or renal disease).&#xD;
&#xD;
          -  Evidence of any other significant clinical disorder or laboratory finding that makes&#xD;
             is undesirable for the subject to participate in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wayne Furman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <results_reference>
    <citation>A Phase I Study of Gefitinib and irinotecan (IRN) in pediatric patients with refractory solid tumors. WL Furman et al. Vol 22, No 14S (July 15 Supplement), 2004: 8521</citation>
  </results_reference>
  <results_reference>
    <citation>Effect of Gefitinib on the bioavailability of oral irinotecan in children with refractory solid tumors. K.R. Crews, W.L. Furman, J.C. Panetta, B.B. Freeman, L.C. Iacono, P.J. Houghton, C.F. Stewart. Proceeding of ASCO. Vol 22, No 14S, 2004:2012.</citation>
  </results_reference>
  <results_reference>
    <citation>Effect of gefitinib on the systemic dispositon of intravenous irinotecan (IRN) in pediatric patients with refractory solid tumors. L.C. Iacono, W.L. Furman, K.R. Crews, J.C. Panetta, B.B. Freeman, N.C. Daw, C.F. Stewart. Proceedings of ASCO. Vol 22, No 14S, 2004:2011.</citation>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Refractory Childhood Solid Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefixime</mesh_term>
    <mesh_term>Cefpodoxime</mesh_term>
    <mesh_term>Cefpodoxime proxetil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

